Chemopreventive effects of 5-aminosalicylic acid on inflammatory bowel disease-associated colorectal cancer and dysplasia: a systematic review with meta-analysis

文献类型： 外文期刊

第一作者： Qiu, Xinyun

作者： Qiu, Xinyun;Ma, Jingjing;Zhang, Hongjie;Wang, Kai

作者机构：

关键词： 5-Aminosalicylic acid;inflammatory bowel disease;chemopreventive effect;colorectal cancer;dysplasia

期刊名称：ONCOTARGET （ 影响因子：5.168； 五年影响因子：5.312 ）

ISSN： 1949-2553

年卷期： 2017 年 8 卷 1 期

页码：

收录情况： SCI

摘要： Background and Aims: The chemopreventive effect of 5-aminosalicylic acid (5-ASA) in patients with inflammatory bowel disease (IBD) has been widely studied; however, the results remain conflicting. The aim of this study was to systematically review the literature and update evidence concerning effects of 5-ASA on the risk of colorectal cancer (CRC) and dysplasia (Dys) in patients with ulcerative colitis (UC) or Crohn's disease (CD). Results: 5-ASA showed a chemopreventive effect against CRC/Dys in IBD patients (OR = 0.58, 95% CI: 0.45-0.75). However, this effect was significant only in clinical-based studies (OR = 0.51; 95% CI: 0.39-0.65), but not in population-based studies (OR = 0.71; 95% CI: 0.46-1.09). Moreover, this effect was noticeable in patients with UC (OR = 0.46, 95% CI: 0.34-0.61), but not in CD (OR = 0.66, 95% CI: 0.42-1.03), and on the outcome of CRC (OR = 0.54, 95% CI: 0.39-0.74), but not Dys (OR = 0.47; 95% CI: 0.20-1.10). In IBD patients, mesalazine dosage >= 1.2g/day showed greater protective effects against CRC/Dys than dosages < 1.2 g/day. However, Sulphasalazine therapy did not show any noticeable protective function regardless of the dosage administered. Materials and Methods: We performed a systematic review with a meta-analysis of 26 observational studies involving 15,460 subjects to evaluate the risks of developing CRC and Dys in IBD patients receiving 5-ASA treatment. Pooled odds ratios (ORs) and 95% confidence intervals (CIs) were calculated for each evaluation index. Conclusions: 5-ASA has a chemopreventive effect on CRC (but not Dys) in IBD patients. Moreover, UC patients can benefit more from 5-ASA than CD patients. Mesalazine maintenance dosage >= 1.2 g/day is an effective treatment for reducing CRC risk in IBD patients.

分类号：

  • 相关文献

[1]Clostridium butyricum partially regulates the development of colitis-associated cancer through miR-200c. Xiao, Y.,Li, K.,Gui, G.,Yang, H.,Xiao, Y.,Li, K.,Gui, G.,Yang, H.,Dai, X.,Liu, J..

[2]A sequence-selective electrochemical DNA biosensor based on HRP-labeled probe for colorectal cancer DNA detection. Wang, Zhijie,Leng, Kailiang,Yang, Yunhui,Li, Jishan,Zheng, Fan,Shen, Guoli,Yu, Ruqin.

[3](-)-Epigallocatechin-3-gallate and EZH2 inhibitor GSK343 have similar inhibitory effects and mechanisms of action on colorectal cancer cells. Ying, Le,Xu, Ping,Zhao, Yueling,Wang, Yuefei,Ying, Le,Yan, Feng,Williams, Bryan R. G.,Xu, Dakang,Ying, Le,Yan, Feng,Williams, Bryan R. G.,Xu, Dakang,Li, Xin,Hu, Yiqun,Xu, Dakang,Dai, Jing. 2018

[4]Simultaneous Incorporation of 5-Fluorouracil and Leucovorin into Chitosan Nanoparticle as Drug Carrier and Its Characterization. Li, Puwang,Wang, Yichao,Kong, Lingxue,Peng, Zheng,Kong, Lingxue. 2010

[5]Anticancer effects of sweet potato protein on human colorectal cancer cells. Li, Peng-Gao,Mu, Tai-Hua,Deng, Le,Li, Peng-Gao,Li, Peng-Gao.

[6]Toxicarioside O induces protective autophagy in a sirtuin-1-dependent manner in colorectal cancer cells. Huang, Yong-Hao,Sun, Yan,Huang, Feng-Ying,Li, Yue-Nan,Wang, Cai-Chun,Tan, Guang-Hong,Huang, Canhua,Huang, Yong-Hao,Sun, Yan,Huang, Feng-Ying,Li, Yue-Nan,Wang, Cai-Chun,Tan, Guang-Hong,Huang, Canhua,Mei, Wen-Li,Dai, Hao-Fu,Huang, Canhua,Huang, Canhua. 2017

作者其他论文 更多>>

微信小程序